← Back to Search

Carbonic Anhydrase Inhibitor

Acetazolamide for Multiple Sclerosis (perfuseMS Trial)

Phase 2
Waitlist Available
Led By John Lincoln, MD, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

perfuseMS Trial Summary

This trial will study how a drug affects the way new MS lesions form and whether it improves tissue repair.

Eligible Conditions
  • Multiple Sclerosis

perfuseMS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change in Global Cerebral Blood Flow
Secondary outcome measures
Percent Change in Tissue Integrity in White Matter (Fractional Anisotropy)
Percent Change in Tissue Integrity in White Matter (Mean Diffusivity)
Other outcome measures
Composite Changes in Disability Measures

Side effects data

From 2022 Phase 4 trial • 11 Patients • NCT03377049
9%
External Ventricular Drainage infection
9%
Hydrocephalus
9%
Pulmonary edema
9%
Cardiomyopathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Acetazolamide Challenge

perfuseMS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AcetazolamideExperimental Treatment1 Intervention
Acetazolamide in oral daily divided dose administered for 6 consecutive months
Group II: PlaceboPlacebo Group1 Intervention
Placebo in oral daily divided dose administered for 6 consecutive months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetazolamide
2011
Completed Phase 4
~2910

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
321,019 Total Patients Enrolled
8 Trials studying Multiple Sclerosis
220 Patients Enrolled for Multiple Sclerosis
John Lincoln, MD, PhDPrincipal InvestigatorUTHealth

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
John A. Lincoln 2016. "Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02466074.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top